Arvinas (ARVN) Cash & Equivalents (2017 - 2026)
Arvinas (ARVN) recorded quarterly Cash & Equivalents of $87.3 million in Q1 2026, down 38.91% quarter-over-quarter from $142.9 million in Q4 2025, and up 7.78% on a YoY basis from $81.0 million in Q1 2025.
Arvinas (ARVN) Cash & Equivalents (2017 - 2026) Analysis & Trends
Arvinas' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $87.3 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 7.78% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $87.3 million (up 7.78% YoY), while the FY2025 annual figure was $142.9 million, up 42.19% from the prior year.
- Cash & Equivalents was $87.3 million for Q1 2026 at Arvinas, down from $142.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $311.7 million in Q4 2023 to a low of $62.3 million in Q1 2022.
- Historically, Cash & Equivalents has averaged $116.0 million across 5 years, with a median of $100.5 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 82.0% in 2022, then soared 283.39% in 2023.
- A 5-year view of Cash & Equivalents shows it stood at $81.3 million in 2022, then jumped by 283.39% to $311.7 million in 2023, then tumbled by 67.76% to $100.5 million in 2024, then soared by 42.19% to $142.9 million in 2025, then slumped by 38.91% to $87.3 million in 2026.
- The last three Cash & Equivalents figures came in at $87.3 million (Q1 2026), $142.9 million (Q4 2025), and $101.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 87.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.30 Mn |
| Dec 31, 2025 | 142.90 Mn |
| Sep 30, 2025 | 101.50 Mn |
| Jun 30, 2025 | 114.90 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | 100.50 Mn |
| Sep 30, 2024 | 85.20 Mn |
| Jun 30, 2024 | 154.80 Mn |
| Mar 31, 2024 | 88.00 Mn |
| Dec 31, 2023 | 311.70 Mn |
| Sep 30, 2023 | 113.70 Mn |
| Jun 30, 2023 | 90.60 Mn |
| Mar 31, 2023 | 130.20 Mn |
| Dec 31, 2022 | 81.30 Mn |
| Sep 30, 2022 | 132.60 Mn |
| Jun 30, 2022 | 93.20 Mn |
| Mar 31, 2022 | 62.30 Mn |
| Dec 31, 2021 | 108.30 Mn |
| Sep 30, 2021 | 255.66 Mn |
| Jun 30, 2021 | 48.73 Mn |